Avantis核心固定收益主動型ETF AVIG 深 滬
等待開盤 04-30 09:30:00 美东时间
41.455
-0.185
-0.44%
華盛通- 最 高41.55
- 今 開41.55
- 成交量 26.04万股
- 最 低 41.435
- 昨 收 41.64
- 總市值 176.39万
- 52周最高 42.236
- 市盈率 靜 --
- 換手率 611.89%
- 52周最低 38.8031
- 委 比 3.23%
- 總股本 4.26万
- 歷史最高 42.9611
- 量 比 1.83
- 振 幅 0.28%
- 歷史最低 33.1928
- 每 手 1
- 風險率 0.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BRIEF-Navigator Gas Signs LoI For Sale Of Eight Gas Vessels And Its Shareholding In Unigas Joint Venture For $183 Million
BRIEF-Navigator Gas Signs LoI For Sale Of Eight Gas Vessels And Its Shareholding In Unigas Joint Venture For $183 Million April 15 (Reuters) - Navigator Holdings Ltd 1NV.F : NAVIGATOR GAS ANNOUNCES SIGNING OF NON-BINDING LETTER OF INTENT FOR SALE OF EIGHT GAS VESSELS AND ITS SHAREHOLDING IN UNIGAS J
04-15 14:03
ROI-Iran's Hormuz 'toll booth' set to hardwire higher energy prices: Bousso
ROI-Iran's Hormuz 'toll booth' set to hardwire higher energy prices: Bousso The opinions expressed here are those of the author , a columnist for Reuters By Ron Bousso LONDON, April 9 (Reuters) - The war that closed the Strait of Hormuz has ended - for now. But Tehran's demand to act as toll booth k
04-09 08:01
Liver drug developer Galectin Therapeutics' 2025 net loss narrows on reduced R&D costs
Liver drug developer Galectin Therapeutics' 2025 net loss narrows on reduced R&D costs Overview U.S. biotech's 2025 net loss narrowed as R&D expenses declined after NAVIGATE trial end Company ended 2025 with $17.7 mln cash plus $10 mln credit line, extending runway to April 2027 Outlook Company expe
03-31 20:09
BRIEF-Koninklijke Philips Receives FDA Gives 510(K) Clearance For EchoNavigator R5.0 With DeviceGuide
BRIEF-Koninklijke Philips Receives FDA Gives 510(K) Clearance For EchoNavigator R5.0 With DeviceGuide March 26 (Reuters) - Koninklijke Philips NV PHG.AS : FDA GIVES 510(K) CLEARANCE FOR ECHONAVIGATOR R5.0 WITH DEVICEGUIDE Source text: here Further company coverage: PHG.AS (Gdansk Newsroom) (( gdansk
03-26 21:12
BRIEF-Xona Closes $170M Series C To Lead Next Era Of Global Navigation
BRIEF-Xona Closes $170M Series C To Lead Next Era Of Global Navigation XONA CLOSES $170M SERIES C TO LEAD NEXT ERA OF GLOBAL NAVIGATION XONA: SERIES C FUNDING ROUND LED BY MOHARI VENTURES NATURAL CAPITAL Source text: ID:nBw2PQTzHa Further company coverage: [ ]
03-26 20:52
BRIEF-Delta Air Lines Raises Q1 Revenue Guidance On Accelerated Demand Trends In March
BRIEF-Delta Air Lines Raises Q1 Revenue Guidance On Accelerated Demand Trends In March March 17 (Reuters) - Delta Air Lines Inc DAL.N : DELTA AIR LINES INC- RAISES Q1 REVENUE GUIDANCE ON ACCELERATED DEMAND TRENDS IN MARCH - SEC FILING DELTA AIR LINES INC: EXPECT MARCH QUARTER EARNINGS WITHIN INITIAL
03-17 18:53
BRIEF-Ten, Ltd. Reports Profits For The Twelve-Months And Fourth Quarter Ended December 31, 2025
BRIEF-Ten, Ltd. Reports Profits For The Twelve-Months And Fourth Quarter Ended December 31, 2025 March 6 (Reuters) - Tsakos Energy Navigation Ltd TEN.N : TEN, LTD. REPORTS PROFITS FOR THE TWELVE-MONTHS AND FOURTH QUARTER ENDED DECEMBER 31, 2025 TSAKOS ENERGY NAVIGATION LTD QTRLY GROSS REVENUES $222.
03-06 21:56
Regenxbio Q4 R&D expenses rise 18.3% to USD 59.6 million
Regenxbio Q4 R&D expenses rise 18.3% to USD 59.6 million REGENXBIO reported Q4 2025 total revenues of USD 30.3 million and a net loss of USD 67.1 million, or USD 1.30 per share. For FY 2025, total revenues were USD 170.4 million and net loss was USD 193.9 million, or USD 3.76 per share. R&D expenses
03-05 20:06
Galectin Therapeutics To Host Virtual KOL Event On March 10, Focusing On Unmet Need And Current Treatment Landscape For MASH Cirrhosis And Portal Hypertension
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced that it will host a virtual key opinion leader
02-27 05:39
UPDATE 3-GSK's new CEO sticks to bold 2031 sales target, warns of slower 2026 growth
UPDATE 3-GSK's new CEO sticks to bold 2031 sales target, warns of slower 2026 growth Company maintains long-term sales target GSK shifts focus to pipeline expansion, commercial execution Q4 and 2025 sales beat analyst expectations GSK says vaccine and general medicines sales may decline in 2026 Shar
02-04 15:12
